ABNOM
☆ AI Dermatology — Free Service
Germaniyaning 2022 yilgi Stiftung Warentest natijalariga ko'ra, iste'molchilarning ModelDermdan qoniqish darajasi pullik teletibbiyot maslahatlariga qaraganda bir oz pastroq bo'lgan.
Germaniyaning 2022 yilgi Stiftung Warentest natijalariga ko'ra, iste'molchilarning ModelDermdan qoniqish darajasi pullik teletibbiyot maslahatlariga qaraganda bir oz pastroq bo'lgan.
relevance score : -100.0%
ReferencesMa'lumki, Q‑switched Nd:YAG lazer Ota nevusini va shunga o'xshash holatlarni samarali davolaydi. Biz high‑fluence 1064 nm Q‑switched Nd:YAG lazerni g'ayrioddiy joylarda mo'g'ulcha dog'lar ustida, terining yorug'lig'i olib kelmasdan, qanchalik yaxshi ishlashini ko'rish uchun tadqiqot o'tkazdik. Ushbu dog'lar mavjud bo'lgan 61 bemorni o'rganib chiqdik, jami 70 ta jarohatni tekshirdik. Zararlarning yarmi lazer bilan davolangan, qolganlari esa taqqoslash uchun davolanmagan. Melanin darajasini o'lchash uchun Mexameter® nomli tarozi va qurilma yordamida natijalarni baholadik. Bemorlar davolash guruhida o'rtacha 14 oy, kuzatuv guruhida esa 18 oy davomida kuzatildi. Tadqiqot oxirida davolangan va davolanmagan guruhlar o'rtasida shkala ko'rsatkichlari va melanin darajasida sezilarli farqlarni topdik; lazer bilan ishlov berilgan guruh yaxshiroq natijalar ko'rsatdi. High‑fluence Q‑switched Nd:YAG lazer terini oqartirmasdan, bu noodatiy mo'g'ul dog'larni davolashda samarali va xavfsiz ekanligini isbotladi.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
Biz ABNOM uchun maxsus lazer bilan davolashning samaradorligi va xavfsizligini o'rganib chiqdik, shuningdek, uning qanchalik yaxshi ishlashiga qanday omillar ta'sir qilishini ko'rib chiqdik. ABNOM bo'lgan va 2‑9 marta lazer bilan davolash olgan 110 bemorni tahlil qildik. Davolanish qancha uzoq davom etsa, shuncha yaxshi natija berishini aniqladik, ammo keksa bemorlarda bu daraja unchalik yuqori emas. Bundan tashqari, terisi engilroq (III turdagi) va ta'sirlangan joylari kichik (10 sm² dan kam) bo'lgan bemorlarda ham yaxshi natija ko'rsatdi. ABNOM bilan birga melazma bo'lishi davolanish samaradorligini pasaytirdi. Ta'sir qilingan joylarning rangi yoki soni natijaga ta'sir qilmadi. Bemorlarning taxminan 10 % da davolanishdan keyin qora dog'lar paydo bo'ldi. Erta bosqichda ko'p davolash yaxshi natijalar berdi. Qorong'i teri va qora dog'lari bo'lgan keksa bemorlarda davolanishdan keyin qora dog'lar paydo bo'lish ehtimoli yuqoriroq. ABNOM va melazma bilan og'rigan bemorlar uchun melazmani yomonlashtirmaslik maqsadida past energiyali lazerdan foydalanish tavsiya etiladi.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ Davolash
Oqartiruvchi vositalar kamdan‑kam yordam beradi. Melazmadan farqli o‘laroq, ABNOM lazer bilan davolash orqali yaxshilanishi mumkin va takrorlanmasdan olib tashlanishi mumkin. ABNOMni davolash uchun lazer seanslari 10‑20 martagacha amalga oshiriladi.
#QS1064 laser